ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,867.08
-0.09%
Dow Jones
42,342.24
0.04%
US Dollar vs MXN
20.30425
-0.22%
Brent Oil
71.85
-0.74%
Bitcoin
94,186.37
-3.36%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Xilio Therapeutics Inc (XLO)

  7. Xilio Therapeutics Inc (XLO) Noticias

Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

NASDAQ
0.938
0.0715
(8.25%)
Cerrado 19 Diciembre 3:00PM
Delayed by 15 minutes
1.25
0.312
( 33.26% )
Pre Mercado: 3:59AM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

XLO Noticias

Solo noticias oficiales

Form 8-K - Current report
Edgar (US Regulatory)
21 horas hace
XLO (8.25%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 Noviembre 2024
XLO (8.25%)

Form 8-K - Current report
Edgar (US Regulatory)
07 Noviembre 2024
XLO (8.25%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
02 Octubre 2024
XLO (8.25%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
27 Septiembre 2024
XLO (8.25%)

XLO Discussion

Ver más
tbonaces80 tbonaces80 42 minutos hace
Strike is easily $1.97. News or approval and we go hard
👍️0
tbonaces80 tbonaces80 10 horas hace
Loaded a nice position here
👍️0
Preciouslife1 Preciouslife1 13 horas hace
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-present-initial-phase-2-data-vilastobart
👍 1
PonkenPlonken PonkenPlonken 3 semanas hace
trades below cash value
Makes no f in sense!
stick it out......
👍️ 1
Preciouslife1 Preciouslife1 1 mes hace
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-clinical-trial-data-phase
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
XLO HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
XLO MONSTER BREAK
👍 1
TrendTrade2016 TrendTrade2016 2 meses hace
XLO BUILDING STEAM
👍 1
PonkenPlonken PonkenPlonken 2 meses hace
running towards two readouts with Gilead sitting at 17% ownership at 1.97$ strike. I have the hubris to say this WILL GO GO
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
XLO HERE WE GO
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
COMING TO LIFE
masked antibodies
👍 1
TrendTrade2016 TrendTrade2016 2 meses hace
XLO...MINI BIO BEAST
👍 1
Laster Laster 2 meses hace
Got some at $1.00 several days ago.
I like the share structure. It might run for a few days.
Looking for $1.40 if I am lucky.
👍️ 1
Preciouslife1 Preciouslife1 2 meses hace
https://ir.xiliotx.com/news-and-events/news-releases
👍️ 1
Preciouslife1 Preciouslife1 3 meses hace
https://www.linkedin.com/posts/hashem-al-ghaili-1b30679b_drug-resistant-bacteria-are-projected-to-activity-7246464071565201410-sAL9?utm_source=share&utm_medium=member_ios
👍️0
Preciouslife1 Preciouslife1 4 meses hace
This information makes one wonder IF BRILICIDIN IS BEING SUPPRESSED TOO: https://www.facebook.com/share/r/MTAzjcdR5iGnab4t/?mibextid=6GsUZ4
👍️ 1
Preciouslife1 Preciouslife1 4 meses hace
https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/gilead-and-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program
👍️0
PonkenPlonken PonkenPlonken 4 meses hace
Gilead paid 13.5mn$ @ 1.97
The results of their partnered program and another one will be reported in Q4 24
masked antibodies... very little toxicity.
I have a small position... Think big rally coming into 2025- atleast to the 1.97 strike.


"Under the License Agreement, the Company will receive approximately $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of approximately $13.5 million in the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a purchase price of $1.97 per share. The Company will be eligible to receive up to $604.0 million in additional contingent payments, which include (i) the proceeds from up to three additional private placements of Common Stock, (ii) the $75.0 million transition fee and (iii) specified development, regulatory and sales-based milestones. Prior to the potential transition fee, up to $29.0 million of the total contingent payments are related to the potential additional private placements of Common Stock and a near-term development milestone. In addition, the Company is eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales."

"In addition, through March 27, 2025, the Company may, at its election and subject to the terms and conditions of the Stock Purchase Agreement, cause Gilead to purchase up to approximately $11.5 million of additional shares of Common Stock (including, at Gilead’s sole election, prefunded warrants in lieu of shares of Common Stock) in up to three additional private placements (each, an “Additional Gilead Private Placement”) at a predetermined price per share..."
👍️ 1
PonkenPlonken PonkenPlonken 7 meses hace
XLO -- unique masking approach and great results. Hot field $JANX. Gilead certainly thinks so - buys real equity. Company trades below the upfront payment...

https://schrts.co/tdtYZDEX
👍️0
Preciouslife1 Preciouslife1 7 meses hace
Hi I tried to buy a bunch of shares this morning once at .885 then at .90; never filled though over the ASK PRICE then it took off upwards! MM MANIPULATION MUCH!?!?
👍️0
Laster Laster 8 meses hace
Stock closed the gap. They are in the right biotech area similar to CLRB and CTMX and SNSE.
Only a matter of time before this explodes to $2 or higher.
JMO.
👍️0
Monksdream Monksdream 8 meses hace
XLO under $2
👍️0
Laster Laster 8 meses hace
The chart shows a very nice looking pennant pattern.
Biotechs are not trading well recently.
Any recovery in biotechs then this could get interesting.
Needs to move past $1.50 to confirm breakout.
Enjoy the day.
👍️0
Laster Laster 8 meses hace
I remember when OCEA had similar pennant pattern before it broke out to $7.50.
Crazy times sometimes causes crazy moves.
I like the story here. Seems like a nice biotech to invest into.
JMO.
Enjoy.
👍️0
Laster Laster 8 meses hace
Oops. I blinked. Missed it.
Maybe I will be quicker when it moves back to $1.20.
Unless it pops to $1.50 on no news.
Chart looks interesting. Nice pennant pattern.
Enjoy.
👍️0
Awl416 Awl416 8 meses hace
Don’t blink
👍️0
Invest-in-America Invest-in-America 9 meses hace
XLO: Best of luck on this one, Capt. TIm!! (I DID get both of your Post-M iHub 'emails', so I am answering both of them vis-a-vis this single one.) I am still in SHOCK that XLO did NOT soar at least 400% today.

WILD, UNPREDICTABLE, DAY TODAY!!! (And I missed all the glory behind @AVTX, to boot!! BUMMER!!!)
👍️0
TIMGZ TIMGZ 9 meses hace
XLO IS MOVING , HOPEFULLY THE TORTOISE-LIKE CONTINUES*****
IN THE NEXT 3 HOURS AND PR MONDAY SHOULD BE MORE GLORIOUS****WE SHALL SEE***


THAT WAS AN EXCELLENT PR BUT THE PLAN ALL ALONG WAS SNAKE-OIL-LIKE
👍️0
Invest-in-America Invest-in-America 9 meses hace
XLO: Worthless piece of SHIT!!!
👍️0
Invest-in-America Invest-in-America 9 meses hace
XLO: Oooooooo, Boy!!! (Latest 'Chart', below, looks pretty good!!!)




"I gots my entire weekly ALLOWANCE in this, sucka!!! So you BETTER gets to Planet Jupiter pretty damn QUICK!!!"
👍️0
Invest-in-America Invest-in-America 9 meses hace
XLO: Halted.
👍️0
JPetroInc JPetroInc 9 meses hace
nice news on XLO

looks a lot like iBio news

good fortunes to all XLO shareholders …

EOM
👍️0
Awl416 Awl416 9 meses hace
Watch out for these dirty algo’s
👍️0
Awl416 Awl416 9 meses hace
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
👍️0
Awl416 Awl416 9 meses hace
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
👍️0
crudeoil24 crudeoil24 3 años hace
Price target > 36.00 > HC Wainwright & Co. analyst Michael King initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $36.

Latest Ratings for XLO DateFirmActionFromTo

Jan 2022HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021Raymond JamesInitiates Coverage OnOutperform Nov 2021Cowen & Co.Initiates Coverage OnOutperform

👍️0
crudeoil24 crudeoil24 3 años hace
TODAY > Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Rene Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4 Annual Oncology Day on Thursday, February 10, 2022, at 8:30 a.m. ET.

A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.
👍️0
crudeoil24 crudeoil24 3 años hace
Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity
👍️0

Su Consulta Reciente

NASDAQ
XLO
Xilio Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados